Galmed Pharma
GLMD0.62103.67% ( +0.0220 )
Galmed Pharma (GLMD)
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications...
- Open
- 0.6042
- High
- 0.6210
- Low
- 0.5405
- Prev. Close
- 0.5990
- Volume
- 140.89K
- Turnover
- 84.73K
- Avg Price
- 0.6014
- Bid/Ask Ratio
- --
- Amplitude
- 13.44%
- 52wk High
- 1.7500
- Volume Ratio
- 1.01
- Turnover Ratio
- 2.21%
Galmed Pharma Analyst Rating
View MoreForecast & Rating
Jun 9, 2026Price forecast
$12.001832.37%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 15 hours ago
The Market's Junk Drawer: Diapers, Jets, and AI's Hidden Backbone
- Global Report · 1 day ago, 04:14 AM
Berkshire's Housing Buyout and Cardinal Health's M&A Blitz Headline Q3 Dealmaking
- Global Report · 2 days ago, 04:19 AM
Safran and United Rentals Raise 2026 Forecasts as M&A Activity Reshapes Mid-Cap Landscapes
- prnewswire · Jul 28 at 06:01 AM
07:00 ETGalmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
- TradingView · Jul 23 at 06:01 AM
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD
- Global Report · Jul 22 at 04:18 AM
From Nuclear Tech to AI Liquid Cooling: Unpacking Micro-Cap Overhauls
